InflaRx shares are trading higher after the company announced GOHIBIC was selected by BARDA for a Phase 2 study on acute respiratory distress syndrome.
Portfolio Pulse from Benzinga Newsdesk
InflaRx shares are trading higher after the company announced that its drug GOHIBIC was selected by BARDA for a Phase 2 study on acute respiratory distress syndrome.
June 24, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InflaRx shares are trading higher following the announcement that its drug GOHIBIC was selected by BARDA for a Phase 2 study on acute respiratory distress syndrome.
The selection of GOHIBIC by BARDA for a Phase 2 study is a significant milestone for InflaRx, indicating potential future success and validation of their product. This positive development is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100